Eleonora Lad, MD
Retina Specialist · Durham, NCNPI 1811150576
Payments from drug & device makers
Across 208 payments — averaging $22,576 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3.3M
- Genentech, Inc.$445K
- Apellis Pharmaceuticals, Inc.$241K
- Janssen Research & Development, LLC$186K
- Boehringer Ingelheim$184K
- F. Hoffmann-la Roche AG$124K
- plus $221K from 14 others
Across 7 payments — averaging $2635.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$12K
- F. Hoffmann-la Roche AG$4K
- Genentech, Inc.$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 9 | $3,294,590 |
| Genentech, Inc. | 9 | $445,434 |
| Apellis Pharmaceuticals, Inc. | 43 | $240,741 |
| Janssen Research & Development, LLC | 31 | $186,187 |
| Boehringer Ingelheim | 4 | $183,680 |
| F. Hoffmann-la Roche AG | 6 | $124,227 |
| Astellas Pharma Global Development | 17 | $68,592 |
| Boehringer Ingelheim International GmbH | 26 | $61,590 |
| Ocular Therapeutix, Inc. | 15 | $38,042 |
| AstraZeneca | 7 | $16,352 |
| Janssen Global Services, LLC | 17 | $16,087 |
| Regeneron | 12 | $8,355 |
| Sanofi US Services Inc. | 1 | $3,413 |
| Regeneron Healthcare Solutions, Inc. | 2 | $2,763 |
| Alcon Research LLC | 3 | $2,219 |
| Astellas Pharma US Inc | 2 | $1,682 |
| Alcon | 1 | $1,000 |
| Alnylam Pharmaceuticals Inc. | 1 | $650 |
| ANI Pharmaceuticals, Inc. | 1 | $122 |
| AbbVie | 1 | $34 |
How this compares
$4,695,761 in reported general payments places this provider in the 95th percentile of 34 retina specialist providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other retina specialist in Durham
- Michael AllinghamDurham$63K
- Oleg AlekseevDurham$4K
- Liangbo ShenDurham$4K
- Jeremy ShawDurham$993
- Michael FliotsosDurham$982
- David SappenfieldDurham$36
- William BridgesAsheville$3.2M
- John ThordsenRaleigh$2.6M
- Cameron StoneAsheville$809K
- Nathan HainesGreensboro$310K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.